The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

nifekalant     6-[2-[2-hydroxyethyl-[3-(4...

Synonyms: CHEMBL360861, SureCN157527, CHEBI:408611, AC1Q6EXU, AK-57422, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of nifekalant


High impact information on nifekalant

  • Nifekalant concentration-dependently increased the force, peak [Ca(2+)](i), and the amplitude of RCCs in Ctr rats but not in MCT rats with identical prolongation of the action potential [5].
  • Nifekalant administration significantly decreased the heart rate and increased systolic blood pressure during AF (P<0.001), and successful cardioversion rapidly further ameliorated these parameters (P<0.001) [3].
  • Nifekalant inhibited HERG channels in a frequency-dependent manner [2].
  • Nifekalant inhibited the HERG current in a concentration-dependent manner with an IC(50) value of 7.9 microM although the drug did not inhibit the minK current in Xenopus oocytes, suggesting selective inhibition of the rapid component of the delayed rectifier K(+) current (I(Kr)) in cardiomyocytes [2].
  • We examined the detailed electrophysiological effects of nifekalant on human-ether-a-go-go-related gene (HERG) channels expressed in Xenopus oocytes [2].

Chemical compound and disease context of nifekalant


Biological context of nifekalant


Anatomical context of nifekalant


Associations of nifekalant with other chemical compounds


Gene context of nifekalant


Analytical, diagnostic and therapeutic context of nifekalant


  1. Mechanisms of destabilization and early termination of spiral wave reentry in the ventricle by a class III antiarrhythmic agent, nifekalant. Yamazaki, M., Honjo, H., Nakagawa, H., Ishiguro, Y.S., Okuno, Y., Amino, M., Sakuma, I., Kamiya, K., Kodama, I. Am. J. Physiol. Heart Circ. Physiol. (2007) [Pubmed]
  2. Inhibitory effect of the class III antiarrhythmic drug nifekalant on HERG channels: mode of action. Kushida, S., Ogura, T., Komuro, I., Nakaya, H. Eur. J. Pharmacol. (2002) [Pubmed]
  3. Enhancing electrical cardioversion and preventing immediate reinitiation of hemodynamically deleterious atrial fibrillation with class III drug pretreatment. Hayashi, M., Tanaka, K., Kato, T., Morita, N., Sato, N., Yasutake, M., Kobayashi, Y., Takano, T. J. Cardiovasc. Electrophysiol. (2005) [Pubmed]
  4. Defibrillation effects of intravenous nifekalant in patients with out-of-hospital ventricular fibrillation. Igarashi, M., Fujino, T., Toyoda, M., Sugino, K., Sasao, K., Sasamoto, S., Otsuka, T., Kobayashi, K., Okano, Y., Yosiwara, K., Koyama, N. Pacing and clinical electrophysiology : PACE. (2005) [Pubmed]
  5. Reduced inotropic effect of nifekalant in failing hearts in rats. Endo, H., Miura, M., Hirose, M., Takahashi, J., Nakano, M., Wakayama, Y., Sugai, Y., Kagaya, Y., Watanabe, J., Shirato, K., Shimokawa, H. J. Pharmacol. Exp. Ther. (2006) [Pubmed]
  6. Anti-arrhythmic efficacy of nifekalant hydrochloride, a pure class III anti-arrhythmic agent, in patients with healed myocardial infarction and inducible sustained ventricular tachycardia. Igawa, M., Aonuma, K., Okamoto, Y., Hiroe, M., Hiraoka, M., Isobe, M. J. Cardiovasc. Pharmacol. (2002) [Pubmed]
  7. Electropharmacological and proarrhythmic effects of a class III antiarrhythmic drug nifekalant hydrochloride assessed using the in vivo canine models. Satoh, Y., Sugiyama, A., Takahara, A., Chiba, K., Hashimoto, K. J. Cardiovasc. Pharmacol. (2004) [Pubmed]
  8. Comparison of nifekalant and lidocaine for the treatment of shock-refractory ventricular fibrillation. Tahara, Y., Kimura, K., Kosuge, M., Ebina, T., Sumita, S., Hibi, K., Toyama, H., Kosuge, T., Moriwaki, Y., Suzuki, N., Sugiyama, M., Umemura, S. Circ. J. (2006) [Pubmed]
  9. Effect of nifekalant, a class III anti-arrhythmic agent, on Ca2+ waves in rat intact trabeculae. Hirose, M., Miura, M., Wakayama, Y., Endo, H., Sugai, Y., Stuyvers, B.D., Kagaya, Y., Watanabe, J., ter Keurs, H.E., Shirato, K. Circ. J. (2005) [Pubmed]
  10. Effects of antiarrhythmic drugs on apoptotic pathways in H9c2 cardiac cells. Isomoto, S., Kawakami, A., Arakaki, T., Yamashita, S., Yano, K., Ono, K. J. Pharmacol. Sci. (2006) [Pubmed]
  11. Effect of nifekalant on acute electrical remodelling in rapid atrial pacing canine model. Tang, M., Zhang, S., Sun, Q., Hua, W., Huang, C.X. Chin. Med. J. (2006) [Pubmed]
  12. Nifekalant hydrochloride administration during cardiopulmonary resuscitation improves the transmural dispersion of myocardial repolarization: experimental study in a canine model of cardiopulmonary arrest. Yoshioka, K., Amino, M., Usui, K., Sugimoto, A., Matsuzaki, A., Kohzuma, K., Kanda, S., Deguchi, Y., Ikari, Y., Kodama, I., Tanabe, T. Circ. J. (2006) [Pubmed]
  13. Nifekalant hydrochloride suppresses severe electrical storm in patients with malignant ventricular tachyarrhythmias. Washizuka, T., Chinushi, M., Watanabe, H., Hosaka, Y., Komura, S., Sugiura, H., Hirono, T., Furushima, H., Tanabe, Y., Aizawa, Y. Circ. J. (2005) [Pubmed]
  14. A fatal case of amiodarone-induced acute respiratory distress syndrome in a patient with severe left ventricular dysfunction due to extensive anterior acute myocardial infarction. Fukumoto, Y., Yamada, A., Ando, H., Sobashima, A., Kuwata, K., Yamawaki, T., Nakamura, R., Eto, Y., Kishi, T., Ikeuchi, M., Sekiya, M., Ozawa, M., Okamatsu, S. Fukuoka Igaku Zasshi (2006) [Pubmed]
  15. Combined effects of nifekalant and lidocaine on the spiral-type re-entry in a perfused 2-dimensional layer of rabbit ventricular myocardium. Amino, M., Yamazaki, M., Nakagawa, H., Honjo, H., Okuno, Y., Yoshioka, K., Tanabe, T., Yasui, K., Lee, J.K., Horiba, M., Kamiya, K., Kodama, I. Circ. J. (2005) [Pubmed]
  16. Sotalol-induced coronary spasm in a patient with dilated cardiomyopathy associated with sustained ventricular tachycardia. Muto, S., Ashizawa, N., Arakawa, S., Tanaka, K., Komiya, N., Toda, G., Seto, S., Yano, K. Intern. Med. (2004) [Pubmed]
  17. Effect of IKr blocker nifekalant on atrial action potential duration after successful internal cardioversion of chronic atrial fibrillation. Kofune, T., Watanabe, I., Okubo, K., Okumura, Y., Masaki, R., Shindo, A., Saito, S. Pacing and clinical electrophysiology : PACE. (2005) [Pubmed]
  18. Prevention of Life-Threatening Ventricular Tachyarrhythmia by a Novel and Pure Class-III Agent, Nifekalant Hydrochloride. Ohashi, J., Yasuda, S., Miyazaki, S., Shimizu, W., Morii, I., Kurita, T., Kawamura, A., Kamakura, S., Nonogi, H. J. Cardiovasc. Pharmacol. (2006) [Pubmed]
  19. Experience with nifekalant hydrochloride in a patient with ischemic cardiomyopathy and severe ventricular dysfunction after dor operation. Kokaji, K., Okamoto, M., Hotoda, K., Kumamaru, H. Japanese heart journal. (2004) [Pubmed]
  20. Effects of intravenous nifekalant, a class III antiarrhythmic drug, on atrial vulnerability parameters in patients with paroxysmal atrial fibrillation. Minami, T., Isomoto, S., Nakao, K., Komiya, N., Fukae, S., Centurion, O.A., Yano, K. Pacing and clinical electrophysiology : PACE. (2004) [Pubmed]
  21. Efficacy of nifekalant hydrochloride in the treatment of fatal ventricular arrhythmia in patients with ischemic heart disease. Ando, J., Kakishita, M., Sakai, K., Komura, Y., Nishiyama, K., Iwabuchi, M., Yokoi, H., Yasumoto, H., Nosaka, H., Nobuyoshi, M. International heart journal. (2005) [Pubmed]
WikiGenes - Universities